|
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors. |
| |
|
Consulting or Advisory Role - Lilly |
Research Funding - Genentech/Roche (Inst); Novartis (Inst); Novartis (Inst) |
| |
|
Consulting or Advisory Role - Celgene |
Research Funding - Genentech (Inst) |
| |
|
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - GE Healthcare; Johnson & Johnson; Teva; Varian Medical Systems |
Consulting or Advisory Role - Ventana Medical Systems |
Patents, Royalties, Other Intellectual Property - Patent for non-invasive methods of leukemia cell detection with MRI/MRS - Patent No. 8894975 |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - EUSA Pharma |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Bayer |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
|
Stock and Other Ownership Interests - Roche |
| |
|
|
Stock and Other Ownership Interests - Genentech |
| |
|
No Relationships to Disclose |
| |
|
Employment - Roche; Strasbourg University Hospital |
| |
|
|
Stock and Other Ownership Interests - Ignyta |
Consulting or Advisory Role - Roche/Genentech |
| |
|
Research Funding - Ignyta (Inst); Novartis (Inst) |
Other Relationship - Helsinn Therapeutics |
| |
|
Stock and Other Ownership Interests - Pfizer |
Research Funding - Merck (Inst); Roche (Inst) |